JPRN-UMIN000033003招募中未知
Circulating tumor DNA for minimal residual disease in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant: a multi-center prospective study. - ctDNA for MRD with AML after transplant.KSGCT1702(ctDNA)
Kanto Study Group for Cell Therapy0 个研究点目标入组 70 人开始时间: 2018年6月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Any patient who decline to register 2.Any patient who are considered as inappropriate to register by attending physician
研究者
相似试验
招募中
不适用
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancerNL-OMON24467Erasmus Medical Center95
进行中（未招募）
1 期
CIRCULATE - A TRIAL TO IMPROVE CARE OF PATIENTS AFTER COLON TUMOR SURGERY, BASED ON AN INNOVATIVE MARKER: CIRCULATING TUMOR DNAstage II colon cancer, after tumour resectionEUCTR2019-000935-15-FRCentre Hospitalier Universitaire (CHU) de Dijon1,980
招募中
不适用
Circulating Tumour DNA in Stage 1 to 4 Ovarian CancerOvarian cancerACTRN12617001119381Walter and Eliza Hall Institute of Medical Research100
招募中
不适用
ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaEsophageal Squamous Cell CarcinomaNCT05426850Fudan University100
进行中（未招募）
不适用
Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerStage II-III Gastric CancerNCT06157216Qilu Hospital of Shandong University65